Vildagliptin: 7 agencies, 2008–2016
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where vildagliptin met resistance it was usually narrowed rather than refused: 4 of 11 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 8.2 years, from 7 Apr 2008 at SMC (Scotland) to 2016 at PBAC (Australia).
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Nothing has been added since 2016; on this evidence the file is dormant.
7 distinct indication wordings are recorded for vildagliptin by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess vildagliptin, on 7 Apr 2008; PBAC (Australia) did not open a file until 2016 — an unusually long tail of 8.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 11 decisive outcomes narrowed vildagliptin to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
4 of the 7 agencies here assessed vildagliptin more than once, SMC (Scotland) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for vildagliptin.
The full ledger for vildagliptin reads 6 recommended, 4 restricted, 3 other and 2 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2016 | Type 2 diabetes mellitus | The PBAC recommended the PBS listing of vildagliptin in triple oral combination with metfo… | source |
| PHARMAC (New Zealand) | 13 Aug 2015 | Diabetes - type 2 | PTAC advice: Recommended for funding with no priority · decision reached | source |
| G-BA (Germany) | 21 May 2015 | Jalra — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 29 Oct 2014 | Indication extension | ASMR V | source |
| SMC (Scotland) | 9 Dec 2013 | Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with the… | accepted (restricted) | source |
11 further decisions for vildagliptin, across 5 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- tirzepatide — divergent outcome (recommended vs not recommended) on a shared indication
- exenatide — divergent outcome (recommended vs not recommended) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
Coverage: 16 decisions for vildagliptin from 7 agencies, 2008 to 2016. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.